"This was a pivotal trial in establishing the safety and efficacy of tenecteplase as an alternative to alteplase in the thrombolytic treatment of acute ischemic stroke within 4.5 hours in Asian ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Despite concerns ...

PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...

LOS ANGELES -- Tenecteplase (TNKase) used off-label as the routine standard for stroke thrombolysis at one Texas stroke network was both feasible and safe, according to the early experience switching ...

Please provide your email address to receive an email when new articles are posted on . Intra-arterial alteplase after successful reperfusion with mechanical thrombectomy for large vessel occlusion ...

Among patients presenting directly to a thrombectomy-equipped center with a large-vessel ischemic stroke, going directly to the endovascular suite and forgoing initial IV thrombolytic therapy provides ...

A newer type of "clot-busting" medication might be safer than the one long used for treating strokes, a preliminary study hints. Researchers found that among nearly 7,900 stroke sufferers, those ...

The cost of tissue plasminogen activator (tPA), or alteplase, a clot-busting drug used to treat stroke patients, has doubled in the past decade, while reimbursement to hospitals for the use of tPA has ...

For patients who present to a thrombectomy-capable center, a direct trip to endovascular therapy does not improve functional outcomes compared with the guideline-recommended approach of giving IV ...